U.S. flag

An official website of the United States government

NM_001130144.3(LTBP3):c.2947A>G (p.Ile983Val) AND Brachyolmia-amelogenesis imperfecta syndrome

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jun 24, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003593091.2

Allele description [Variation Report for NM_001130144.3(LTBP3):c.2947A>G (p.Ile983Val)]

NM_001130144.3(LTBP3):c.2947A>G (p.Ile983Val)

Genes:
LOC121832793:Sharpr-MPRA regulatory region 4001 [Gene]
LTBP3:latent transforming growth factor beta binding protein 3 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
11q13.1
Genomic location:
Preferred name:
NM_001130144.3(LTBP3):c.2947A>G (p.Ile983Val)
HGVS:
  • NC_000011.10:g.65540901T>C
  • NG_016437.1:g.22328A>G
  • NG_075883.1:g.384T>C
  • NG_075883.2:g.883T>C
  • NM_001130144.3:c.2947A>GMANE SELECT
  • NM_001164266.1:c.2596A>G
  • NM_021070.4:c.2947A>G
  • NP_001123616.1:p.Ile983Val
  • NP_001157738.1:p.Ile866Val
  • NP_066548.2:p.Ile983Val
  • NC_000011.9:g.65308372T>C
Protein change:
I866V
Molecular consequence:
  • NM_001130144.3:c.2947A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001164266.1:c.2596A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_021070.4:c.2947A>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Brachyolmia-amelogenesis imperfecta syndrome
Synonyms:
Verloes Bourguignon syndrome; Skeletal dysplasia with amelogenesis imperfecta and platyspondyly; Platyspondyly with amelogenesis imperfecta; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0011018; MedGen: C1832594; Orphanet: 2899; OMIM: 601216

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV004284683Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Jun 24, 2023)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group, Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV004284683.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. This variant has not been reported in the literature in individuals affected with LTBP3-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 983 of the LTBP3 protein (p.Ile983Val).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024